SpringWorks Therapeutics Inc [SWTX] stock is trading at $45.20, up 5.24%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SWTX shares have gain 6.96% over the last week, with a monthly amount glided 4.15%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
SpringWorks Therapeutics Inc [NASDAQ: SWTX] stock has seen the most recent analyst activity on February 05, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $75. Previously, BofA Securities started tracking the stock with Buy rating on December 01, 2022, and set its price target to $45. On January 19, 2021, H.C. Wainwright reiterated its Buy rating and revised its price target to $101 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $73 on October 29, 2020. Barclays initiated its recommendation with a Overweight and recommended $48 as its price target on May 05, 2020. H.C. Wainwright upgraded its rating to Buy for this stock on March 19, 2020, and upped its price target to $60. In a note dated March 04, 2020, H.C. Wainwright downgraded an Neutral rating on this stock but restated the target price of $40.
SpringWorks Therapeutics Inc [SWTX] stock has fluctuated between $18.00 and $53.92 over the past year. Currently, Wall Street analysts expect the stock to reach $73.33 within the next 12 months. SpringWorks Therapeutics Inc [NASDAQ: SWTX] shares were valued at $45.20 at the most recent close of the market. An investor can expect a potential return of 62.23% based on the average SWTX price forecast.
Analyzing the SWTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -9.49%, Pretax Profit Margin comes in at -8.95%, and Net Profit Margin reading is -8.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -0.66 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.12 points at the first support level, and at 43.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.01, and for the 2nd resistance point, it is at 46.83.
Ratios To Look Out For
For context, SpringWorks Therapeutics Inc’s Current Ratio is 6.85. In addition, the Quick Ratio stands at 6.77 and the Cash Ratio stands at 1.71. Considering the valuation of this stock, the price to sales ratio is 126.61, the price to book ratio is 5.90.
Transactions by insiders
Recent insider trading involved Pichl Daniel, Chief People Officer, that happened on Feb 16 ’24 when 15000.0 shares were sold. Chief Commercial Officer, Ashar Bhavesh completed a deal on Feb 05 ’24 to sell 4834.0 shares. Meanwhile, Chief People Officer Pichl Daniel sold 26181.0 shares on Feb 02 ’24.
